Karuna obtains rights to Vanderbilt's schizophrenia compounds

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dheiCduTtWCbemeJCidawyCicNtCtg

September 29, 2011 BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more. The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.   Today's Top Story    Karuna obtains rights to Vanderbilt's schizophrenia compounds Karuna Pharmaceuticals licensed from Vanderbilt University a group of compounds that address positive, negative and cognitive symptoms of schizophrenia. The compounds treat the condition by homing in on the glycine transporter one protein, which eliminates glycine from neurons if it goes awry. Xconomy/Boston (9/28)      Special Offer for SmartBrief Readers: How to Win at the Local Marketing Game. Marketing guru John Jantsch gives five strategies for helping any local business to stand out online. Want to help your business get to the top of a consumer's search? Click here for a free white paper from American Express OPEN outlining John's time-tested strategies for success in today's hyperlocal marketplace.   Health Care & Policy    Study: Molecular switches may aid in diabetes prevention, treatment Certain molecular switches prompt pancreatic beta islet cells to multiply and grow, which may bolster insulin production, experts reported in the Proceedings of the National Academy of Sciences. Finding ways to trigger pancreatic cells to produce sufficient amounts of insulin may offer a treatment for type 1 diabetes or help boost diabetes prevention, the study lead author said. Yahoo!/Asian News International (9/27)      MIT professor gets national medal for stem cell work Rudolf Jaenisch, a biology professor at the Massachusetts Institute of Technology, has received the National Medal of Science. Jaenisch has been recognized for his research into stem cells and epigenetics. He is using adult stem cells to develop treatments for neurological conditions, including Parkinson's disease. The Boston Globe/White Coat Notes blog (free registration) (9/27)      Researchers work on malaria vaccine U.S. researchers are developing a malaria vaccine using a disabled cold virus with a gene that stimulates the immune system. The vaccine is designed to target the circumsporozoite protein in the malaria parasite. Researchers think the protein plays a role in triggering an immune response to malaria. Findings of the study were published in the journal PLoS ONE. Medindia.net (India)/Asian News International (9/27)      LET’S GO DESIGN: Episode #4 In this episode of SolidWorks’ interactive web series, host Jeremy Luchini starts designing the chassis of the Hot Rod Baby Buggy using weldment features and sketch techniques. He also visits a metal fabrication shop to learn about methods that will help in building our project. Watch the new episode now at LetsGoDesign.tv   Company & Financial News    Second review backs strength of Cell Therapeutics' pixantrone data Cell Therapeutics said a second independent radiology review of data from a study of pixantrone, a drug candidate for non-Hodgkin's lymphoma, showed "significant results" and validated the "statistical robustness" of clinical data filed with the FDA. The company said it plans to resubmit an application as early as next month for accelerated approval of the drug. American City Business Journals/Seattle (9/28)      Onyx seeks expedited FDA review of myeloma drug carfilzomib Onyx Pharmaceuticals requested FDA priority evaluation of carfilzomib, a treatment candidate for multiple myeloma. The drugmaker is banking on clinical data showing that the drug reduces tumor size in patients who have received at least two previous therapies. Xconomy/San Francisco (9/28)      Athersys unveils details of Phase II trial for MultiStem therapy Athersys will start enrolling patients in a midstage trial of its MultiStem treatment for ischemic stroke this month. The randomized study will involve about 140 patients and is expected to conclude by November 2014. MedCityNews.com (9/28)      Health care reform got you down? Learn more from UnitedHealthcare on how the federal changes to medical benefits will affect you and your employees. This guide highlights incentives for enrollment and a timeline of important dates and deadlines. Don't let them pass you by—Learn more here!   Industry Deals    Biotie-Newron merger will create CNS-focused biopharma firm Biotie Therapies and Newron Pharmaceuticals agreed to a $61 million merger to form a biopharmaceutical firm that specializes in therapies for the central nervous system. The company's pipeline will include key late-stage candidates safinamide for Parkinson's disease and nalmefene for alcohol dependence. The drugmakers expect to complete the merger by Oct. 31. PharmaTimes (U.K.) (9/27)      Enterprise Resource Planning automates many aspects of an organization's operations, cascading across traditional boundaries of operations, finance, manufacturing and more. As such, changes in the ERP market can cause a ripple effect in your business. Get ahead of the changing tide and trends by downloading this free whitepaper.   Featured Content    King Nerd: How Robert Stephens Founded And Grew Geek Squad Katie Morell 7 Ways To Get More Value From Your Values Ken Kaufman The 5 Steps To Managing A Disgruntled Employee Mike Michalowicz 2 Social Networks That Will Help You Meet People TJ McCue Small Business In America: 10 Years After 9/11 Susan L. Reid   Food & Agriculture  Monsanto acquires biological pest control firm Monsanto has agreed to acquire Beeologics, a startup that develops biological tools to control pests and plant diseases without causing harm to bees, for an undisclosed amount. Monsanto said the acquisition would enable it to expand the use of biological technologies in agriculture. American City Business Journals/St. Louis (9/28)        Industrial & Environmental  USDA issues almost $80M to 163 advanced-biofuel developers The Department of Agriculture announced that it will issue a total of nearly $80 million to 163 advanced-biofuel producers. "The payments I am announcing today represent the continuing commitment of the Obama administration to work with producers to provide the biofuel necessary to reduce our nation's dependence on foreign energy sources," said Agriculture Secretary Tom Vilsack. Agriculture.com/Dow Jones Newswires (9/27)        News from BIO  BIOtechNOW BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter.      Learn more about BIO -> Conferences  |  Join BIO  |  Media  |  Issues  |  Industry   SmartQuote  Where one conviction is lacking, a thousand opinions will do -- indeed they become a necessary recourse." --Roger Lowenstein, American financial journalist          This SmartBrief was created for jmabs1@gmail.com   Subscriber Tools       Update account information | Change e-mail address | Unsubscribe | Print friendly format | Web version | Search past news | Archive | Privacy policy Advertise Account Director:  Meryl Harold (202) 407-7828 Download Media Kit   Read more at SmartBrief.com A powerful website for SmartBrief readers including: Industry Home Readers' Choice Search Archive Grab our News Widget Get this RSS Feed Publish your Press Release Download a SmartBrief Mobile app today       Recent BIO SmartBrief Issues: Wednesday, September 28, 2011 Tuesday, September 27, 2011 Monday, September 26, 2011 Friday, September 23, 2011 Thursday, September 22, 2011     Lead Editor:  Adam Gaub       Mailing Address: SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005     © 1999-2011 SmartBrief, Inc.® Legal Information